Selective serotonin reuptake inhibitors in Major Depressive Disorder in children and adolescents (ratio of benefits/risks);Indication des inhibiteurs de la recapture de la sérotonine au cours d'un Épisode Dépressif Majeur chez l'enfant et l'adolescent (bénéfices/risques)

Encephale

Volumn 31, Issue 3, 2005, Pages 309-316

  Hjalmarsson, L ^a   Corcos, M ^a   Jeammet, Ph ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Adolescents; Children; Major depressive disorders; SSRI; Suicide

Indexed keywords

FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; ANHEDONIA; CHILD; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL DISEASE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PSYCHOTHERAPY; RATING SCALE; REVIEW; SUICIDE; TREATMENT OUTCOME;

EID: 22544454771     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(05)82395-4     Document Type: Review

References (65)

1. APTER A, PLUTCHIK R, VAN PRAAG HM. Anxiety, impulsivity and depressed mood in relation to suicidal and violent behavior. Acta Psychiatr Scand 1993; 87: 1-5.
2. BASQUIN M, COHEN D. Les psychothérapies de la dépression avant 20 ans. In: Dépression avant 20 ans. Paris: Masson, 1998.
3. BIRMAHER B, BRENT DA, BENSON RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1998; 37 (11): 1234-8.
4. BIRMAHER B, RYAN ND, WILLIAMSON DE et al. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1427-39.
5. BIRMAHER B, RYAN ND, WILLIAMSON DE et al. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 1996; 35 (12): 1575-83.
6. BRACONNIER A, LE COENT R, COHEN D. DEROXADO Study Group. Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003; 42 (1): 22-9.
7. BRENT DA, BIRMAHER B. British warnings on SSRI questionned. J Am Acad Child Adolesc Psychiatry 2004, 43: 4.
8. BRENT DA, BAUGHER M, BRIDGE J et al. Age and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry 1999; 38 (12): 1497-505.
9. BRENT DA, KALAS R, EDELBROCK C et al. Psychopathology and its relationship to suicidal ideation in childhood and adolescence. J Am Acad Child Psychiatry 1986; 25: 666-73.
10. BRETON JJ, TOUSIGNANT M, BERGERON L et al. Informant-specific correlates of suicidal behavior in a community survey of 12 to 14 year-old. J Am Acad Child Adolesc Psychiatry 2002; 41 (6): 723-30.
11. BROWN LK, OVERHOLSER J, SPIRITO A et al. The correlates of planning in adolescent suicide attempts. J Am Acad Child Adolesc Psychiatry 1991; 30: 95-9.
12. CARLSON GA. Child and adolescent mania-diagnostic considerations. J Child Psychol Psychiatry 1990; 31 (3): 331-41.
13. COMMITTEE ON SAFETY OF MEDICINES. Use of selective serotonin reuptake inhibitors (SRRIs) in children and adolescents with major depressive disorder (MDD). www.mhra.gov.uk/(accessed, 16 December 2003).
14. CORCOS M. Prescription des psychotropes à l'adolescence. Perspect Psychiatr 2004; 43 (1): 42-8.
15. DE SIMONE A, MURRAY P, LESTER D. Alcohol use, self-esteem, depression, and suicidality in high school students. Adolescence 1994; 29 (116): 939-42.
16. EMSLIE GJ, HEILIGENSTEIN JH, WAGNER KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1205-15.
17. EMSLIE GJ, RUSH AJ, WEINBERG WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-7.
18. FINDLING RL, MCNAMARA NK, O'RIORDAN MA et al. An open-label pilot study of St. John's worth in juvenile depression. J Am Acad Child Adolesc Psychiatry 2003; 42 (8): 908-14.
19. FINDLING RL, MYERS C, O'RIORDAN MA et al. An open-label dosing study of paroxetine in depressed youths. Curr Ther Res 2002; 63: 588-601.
20. FLAMENT MF, COHEN D, CHOQUET M et al. Phenomenology, psychosocial correlates and treatment seeking in major depression and dysthymia of adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40 (9): 1070-8.
21. FOOD AND DRUG ADMINISTRATION. Reports of suicidality in pediatric patients being treated with antidepressive medications for major depressive disorder (MDD). FDA Talk Paper T03-70 (27 October 2003) www.fda.gov/bbs/topics/ ANSWERS/2003/ANS01256.html (accessed 12 December 2003).
22. FOOD AND DRUG ADMINISTRATION. Approves Prozac for Pediatric Use to Treat Depression and OCD. FDA Talk Paper T03-01 www.fda.gov/bbs/topics/ANSWERS/ 2003ANS01187 (3 January 2003).
23. GERSHON AA, DANNON PN, GRUNHAUS L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003; 160 (5): 835-45.
24. GUY W. ECDEU Assessment Manual for Psychopharmacology. Washington DC: US Department of Health, Education and Welfare, 1976.
25. HAMMEN C, RUDOLPH K, WEISZ J et al. The context of depression in clinic-referred youth: neglected areas in treatment. J Am Acad Child Adolesc Psychiatry 1999; 38 (1): 64-71.
26. HARRINGTON R, WHITTAKER J, SHOEBRIDGE P. Psychological treatment of depression in children and adolescents. A review of treatment research. Br J Psychiatry 1998; 173: 291-8.
27. HAZELL P, O'CONNELL D, HEATHCOTE D et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2003; (4).
28. HAZELL P, O'CONNELL D, HEATHCOTE D et al. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis BMJ 1995; 310: 897-901.
29. KAUFMAN J, MARTIN A, KING RA et al. Are child, adolescent, and adult-onset depression one and the same disorder? Biol Psychiatry 2001; 49(12): 980-1001.
30. KELLER MB, RYAN ND, STROBER M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (7): 762-72.
31. KHAN A, KHAN S, KOLT R et al. Suicide rates in clinical trials of SSRIS, other antidepressants and placebo; analysis of FDA reports. Am J Psychiatry 2003; 160: 790-2.
32. KHAN A, WARNER HA, BROWN WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57 (4): 311-7.
33. KUTCHER S, BOULOS C, WARD B et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 1994; 33: 686-94.
34. LEWINSOHN PM, ROBERTS RE, SEELEY JR. Psychosocial characteristics of adolescents with a history of suicide attempt. J Am Acad Child Adolesc Psychiatry 1993, 32: 60-8.
35. LEWINSOHN PM, ROHDE P, SEELEY JR et al. Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry 2000; 157 (10): 1584-91.
36. MANDOKI MW, TAPIA MR, TAPIA MA et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997; 33 (1): 149-54.
37. MASI G, MARCHESCHI M, PFANNER P. Paroxetine in depressed adolescents with intellectual disability: an open label study. J Intellect Disabil Res 1997; 41 (Pt 3): 268-72.
38. McKEOWN RE, GARRISON CZ, CUFFE SP et al. Incidence and predictors of suicidal behaviors in a longitudinal sample of young adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37 (6): 612-9.
39. MILIN R, WALKER S, CHOW J. Major depressive disorder in adolescence: a brief review of the recent treatment literature. Can J Psychiatry 2003; 48 (9): 600-6.
40. MITKA M. FDA alert on antidepressants for youth. JAMA 2003; 290 (19): 25-34.
41. MUFSON L, WEISSMAN MM, MOREAU D et al. Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 1999; 56 (6): 573-9.
42. MULDER RT, WATKINS WG, JOYCE PR et al. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord 2003; 76 (1-3): 143-9.
43. OLFSON M, GAMEROFF MJ, MARCUS SC et al. Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry 2003; 60 (12): 1236-42.
44. OLFSON M, SHAFFER D, MARCUS SC et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60 (10): 978-82.
45. PAPATHEODOROU G, KUTCHER S. The effect of adjunctive light therapy on ameliorating breakthrough depressive symptoms in adolescent-onset bipolar disorder. J Psychiatry Neurosci 1995; 20 (3): 226-32.
46. POZNANSKI EO, FREEMAN LN, MOKROS HB. Children's depressive rating scale-revised. Psychopharmacol Bull 1985; 21: 979-89.
47. RAO U, RYAN ND, BIRMAKER B et al. Unipolar depression in adolescents: clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 1995; 34: 566-78.
48. RAO U, WEISSMAN MM, MARTIN JA et al. Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry 1993; 32 (1): 21-7.
49. REIST C, NAKAMURA K, SAGART E et al. Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry 2003; 64 (1): 81-5.
50. REY-SANCHEZ F, GUTIERREZ-CASARES JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry 1997; 36 (10): 1443-7.
51. RHODE P, LEWINSOHN PM, SEELEY JR. Symptoms of DSM III-R major depression in adolescence: evidence from an epidemiological survey. J Am Acad Child Adolesc Psychiatry 1991; 34: 1608-17.
52. RIDDLE MA, GELLER B, RYAN N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32 (4): 792-7.
53. RINTELMANN JW, EMSLIE GJ, RUSH AJ et al. The effects of extended evaluation on depressive symptoms in children and adolescents. J Affect Disord 1996; 41 (2): 149-56.
54. ROBERTS RE, ROBERTS CR, CHEN YR. Suicidal thinking among adolescents with a history of attempted suicide. J Am Acad Child Adolesc Psychiatry 1998; 37 (12): 1294-300.
55. RYAN ND, PUIG-ANTICH J, AMBROSINI P et al. The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry 1987; 44 (10): 854-61.
56. SIMEON JG, DINICOLA VF, FERGUSON HB et al. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14 (5): 791-5.
57. STROBER M, DEANTONIO M, SCHMIDT-LACKNER S et al. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. J Clin Psychiatry 1999; 60 (3): 164-9.
58. SWEDO SE, ALLEN AJ, GLOD CA et al. A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder. J Am Acad Child Adolesc Psychiatry 1997; 36 (6): 816-21.
59. TREATMENT FOR ADOLESCENTS WITH DEPRESSION STUDY (TADS). Rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42 (5): 531-42.
60. WAGNER KD, AMBROSINI P, RYNN M et al. Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacol Bull 2003; 37 (Suppl 1): 167-75.
61. WAGNER KD, AMBROSINI P, RYNN M et al. Sertraline Pediatric Depression Study Group. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290 (8): 1033-41.
62. WAGNER K. Citalopram in pediatric major depression. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, 2001.
63. WEISSMAN MM, WOLKS, GOLDSTEIN RB et al. Depressed adolescents grown up. JAMA 1999; 281 (18): 1707-13.
64. WHITMORE EA, MIKULICH SK, THOMPSON LL et al. Influences on adolescent substance dependence: conduct disorder, depression, attention deficit hyperactivity disorder, and gender. Drug Alcohol Depend 1997; 47 (2): 87-97.
65. WHITTINGTON CJ, KENDALL T, FONAGY P et al. Selective serotonin reuptake inhibitors in childhood depression. Lancet 2004; 363 (9418): 1341-5.